The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is a huge mover today! About 192,699 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 10.41% since March 7, 2016 and is uptrending. It has outperformed by 2.82% the S&P500.
The move comes after 5 months positive chart setup for the $2.24 billion company. It was reported on Oct, 10 by Barchart.com. We have $93.54 PT which if reached, will make NASDAQ:AGIO worth $1.55 billion more.
Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on November, 3. They expect $-1.44 earnings per share, down 34.58% or $0.37 from last year’s $-1.07 per share. After $-1.47 actual earnings per share reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -2.04% EPS growth.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage
Out of 11 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. Agios Pharmaceuticals has been the topic of 19 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Wednesday, May 18 by Credit Suisse. Suntrust Robinson maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, May 18 with “Buy” rating. The rating was maintained by TH Capital with “Neutral” on Monday, November 9. Canaccord Genuity maintained it with “Hold” rating and $93 target price in Friday, August 7 report. The firm earned “Outperform” rating on Thursday, July 23 by Northland Capital. Janney Capital initiated the shares of AGIO in a report on Wednesday, March 2 with “Neutral” rating. SunTrust initiated Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, March 30 with “Buy” rating. As per Friday, August 19, the company rating was initiated by BTIG Research. The rating was maintained by Roth Capital on Wednesday, August 5 with “Hold”. The firm has “Overweight” rating given on Monday, June 13 by JP Morgan.
According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.03, from 1.36 in 2016Q1. The ratio increased, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Finemark National Bank & Trust Trust last reported 0% of its portfolio in the stock. Winfield Assoc accumulated 10 shares or 0% of the stock. Art Advsrs Lc has 0.02% invested in the company for 10,202 shares. Arrowpoint Asset Mngmt Limited Co owns 85,405 shares or 0.07% of their US portfolio. Cap Limited Ca owns 260,600 shares or 0.79% of their US portfolio. Intl Grp Inc last reported 0% of its portfolio in the stock. Morgan Stanley has 0% invested in the company for 106,904 shares. The New York-based Citigroup Inc has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Tocqueville Asset Management Ltd Partnership accumulated 0.01% or 13,600 shares. Ameriprise Financial has 22,029 shares for 0% of their US portfolio. Proshare has invested 0.02% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Lord Abbett & Limited Liability Corporation owns 411,920 shares or 0.05% of their US portfolio. Teacher Retirement Systems Of Texas has 3,921 shares for 0% of their US portfolio. Wellington Mgmt Llp reported 5.31 million shares or 0.06% of all its holdings. National Bank & Trust Of Montreal Can last reported 5,523 shares in the company.
Insider Transactions: Since April 25, 2016, the stock had 0 insider buys, and 8 sales for $2.91 million net activity. $129,432 worth of shares were sold by Cantley Lewis Clayton Jr. on Wednesday, May 25. Shares for $275,000 were sold by Biller Scott on Wednesday, October 5.
More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Fool.com which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also Fool.com with their article: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” published on July 03, 2016, Fool.com published: “Why Agios Pharmaceuticals Inc. Presented Lower Today” on June 09, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: Fool.com and their article: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” published on May 06, 2016 as well as Fool.com‘s news article titled: “The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January” with publication date: February 06, 2016.
AGIO Company Profile
Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.